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It	   is	   unclear	   whether	   prior	   endemic	   coronavirus	   infections	   affect	   COVID-­‐19	   severity.	  
Here,	  we	  show	   that	   in	   cases	  of	   fatal	  COVID-­‐19,	  antibody	  responses	   to	   the	  SARS-­‐COV-­‐2	  80 
spike	   are	  directed	   against	   epitopes	   shared	  with	   endemic	  beta-­‐coronaviruses	   in	   the	   S2	  
subunit	  of	   the	  SARS-­‐CoV-­‐2	  spike	  protein.	  This	   immune	  response	   is	  associated	  with	  the	  
compromised	   production	   of	   a	   de	   novo	   SARS-­‐CoV-­‐2	   spike	   response	   among	   individuals	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Introduction	  
	  90 
Four	  human	  coronaviruses	  (HCoV)	  are	  currently	  considered	  endemic	  worldwide.	  These	  
include	   two	   beta-­‐coronaviruses,	   HCoV-­‐OC43	   and	   HCoV-­‐HKU1,	   as	   well	   as	   two	   alpha-­‐
coronaviruses,	  HCoV-­‐229E	  and	  HCoV-­‐NL63.	  Infection	  by	  these	  viruses	  in	  the	  majority	  of	  
people	   causes	   a	   mild	   respiratory	   illness	   (1).	   Over	   the	   past	   two	   decades,	   two	   further	  
beta-­‐coronaviruses	  have	  also	  emerged,	  SARS-­‐CoV-­‐1	  and	  MERS-­‐CoV.	  Whilst	  both	  viruses	  95 
have	   been	   more	   pathogenic	   than	   endemic	   coronaviruses,	   their	   transmission	   and	  
subsequent	   spread	   has	   remained	   limited	   (2).	   In	   2019	   a	   fifth	   beta-­‐coronavirus,	   SARS-­‐
CoV-­‐2,	  emerged	  which	  has	  led	  to	  a	  pandemic	  with	  over	  100	  million	  cases	  and	  upwards	  
of	   3	   million	   deaths	   confirmed	   to	   date	   (3).	   Several	   studies	   have	   shown	   that	   prior	  
infection	   with	   other	   HCoVs	   induces	   both	   cross-­‐reactive	   antibody	   and	   T-­‐cell	   cross-­‐100 
reactive	  responses	  to	  SARS-­‐CoV-­‐2	  (4–7).	  However,	  the	  influence	  of	  prior	  HCoV	  exposure	  
on	  COVID-­‐19	  severity	  and	  clinical	  outcome	  remains	  unclear	  (8).	  	  
	  
The	  spike	  protein	  of	  SARS-­‐CoV-­‐2,	  which	  is	  the	  primary	  vaccine	  target,	  consists	  of	  the	  S1	  
and	   S2	   subunits	   (9,10).	   The	   S1	   subunit	   contains	   a	   more	   variable	   receptor-­‐binding	  105 
domain	   (RBD),	  which	  mediates	  viral	   entry	  during	   the	   infection	  process	  via	   interaction	  
with	   the	   angiotensin-­‐converting	   enzyme	   2	   (ACE2)	   receptor.	   Antibodies	   targeting	   the	  
RBD	  can	  be	  neutralising	  and	  have	  been	  shown	  to	  correlate	  with	  protection	  (11).	  HCoV	  
induced	   antibody	   responses	   do	   not	   appear	   to	   cross-­‐react	   with	   the	   SARS-­‐CoV-­‐2	   RBD	  
(9,12),	  or	  at	  least	  do	  so	  infrequently	  (10).	  In	  contrast,	  it	  has	  previously	  been	  reported	  by	  110 
several	   studies	   that	   antibodies	   induced	   by	   prior	   HCoV	   infections	   cross-­‐react	  with	   the	  
SARS-­‐CoV-­‐2	  S2	  subunit	  (7,8,9,10).	  
	  
Cross-­‐reactive	   T-­‐cell	   responses	   have	   also	   been	   reported	   to	   be	   present	   in	   many	  
individuals	  (5,7,16,17),	  which	  may	  have	  been	  induced	  by	  HCoV	  infection.	  These	  studies	  115 
found	   CD4+	   and	   CD8+	   T	   cells	   reactive	   to	   SARS-­‐CoV-­‐2	   spike	   peptide	   pools	   in	   blood	  
samples	   from	   individuals	   unexposed	   to	   SARS-­‐CoV-­‐2	   (5,7,16).	   This	   indicates	   that	   prior	  
exposure	   to	   HCoVs	   could	   confer	   a	   cross-­‐reactive	   T-­‐cell	   response	   in	   a	   subset	   of	   the	  
population	  and	  could	  potentially	  affect	  COVID-­‐19	  severity	  (18).	  	  
	  120 
In	  this	  study,	  to	  determine	  if	  prior	   infection	  by	  HCoVs	  is	  associated	  with	  differences	  in	  
COVID-­‐19	  severity,	  we	  retrospectively	  tested	  samples	  from	  individuals	  who	  previously	  
had	   qRT-­‐PCR-­‐confirmed	   asymptomatic	   infection,	   as	   well	   as	   patients	   admitted	   to	   ICU	  
with	  severe	  COVID-­‐19,	  half	  of	  whom	  died.	  	  













	   4	  
	  125 
We	  also	  analysed	   two	   large	  cohorts	  with	  SARS-­‐CoV-­‐2	  neutralising	  antibodies	  obtained	  
from	  UK	  seroprevalence	  studies:	  one	  containing	  sera	   from	  blood	  donors	  and	  the	  other	  
sera	  collected	  from	  pregnant	  women	  sampled	  <14	  weeks’	  gestation	  (19,20).	  These	  two	  
cohorts	  did	  not	  have	  a	  precise	  clinical	  definition	  of	  SARS-­‐CoV-­‐2	  infection	  severity.	  As	  a	  
third	   control	   cohort,	  we	   included	   SARS-­‐CoV-­‐2	   seronegative	   individuals	   from	   the	   same	  130 
blood	  donor	  seroprevalence	  study	   (20).	  Further	  details	  of	   the	  cohorts	   can	  be	   found	   in	  
Table	  1	  and	  Figures	  S3	  to	  S5.	  	  
	  
By	  comparing	  antibody	  responses	   to	   the	  SARS-­‐CoV-­‐2	  nucleocapsid	  and	  spike	  proteins,	  
we	   show	   that	   individuals	   with	   fatal	   COVID-­‐19	   outcomes	   have	   an	   immune	   response	  135 
directed	  against	  immunologically	  similar	  SARS-­‐CoV-­‐2	  and	  beta-­‐HCoV	  epitopes	  in	  the	  S2	  
subunits	  of	  the	  SARS-­‐CoV-­‐2	  spike	  protein.	  This	  immune	  response	  is	  associated	  with	  the	  
compromised	   generation	   of	   a	   de	   novo	   immune	   response	   to	   the	   SARS-­‐CoV-­‐2	   spike	   in	  
individuals	  with	  fatal	  COVID-­‐19	  outcomes.	  To	  our	  knowledge	  this	  is	  the	  first-­‐time	  prior	  
exposure	   to	   HCoVs	   has	   been	   associated	   with	   COVID-­‐19	   severity	   and	   mapped	   to	   a	  140 














































Individuals with fatal COVID-19 outcomes make lower responses to the SARS-CoV-2 spike 
protein but not the SARS-CoV-2 nucleocapsid 
 175 
We used an MSD V-PLEX assay to quantify total antibody responses to the SARS-CoV-2 
nucleocapsid (N), the RBD, N-terminal domains (NTD) of the spike, the SARS-CoV-2 full-
length spike as well as the spike proteins of the four HCoVs and SARS-CoV-1. In-house 
indirect ELISAs were also developed for the SARS-CoV-2 RBD and full-length spike, in 
addition to the full-length alpha- and beta-HCoV spike proteins to confirm the results 180 
produced by the V-PLEX assay. Both the MSD assay and in-house ELISAs correlated well 
(Figure S1).  
 
We found that the antibody titres to the SARS-CoV-2 spike and nucleocapsid generally 
correlated with increasing COVID-19 severity (Figure 1). However, individuals with fatal 185 
COVID-19 consistently exhibited lower titres to SARS-CoV-2 spike antigens; the SARS-
CoV-2 RBD (p = 0.01), and NTD (p = 0.02) of the spike as well as the full length spike (p = 
0.02) were higher in the non-fatal ICU cohort compared to the fatal ICU cohort (Figure 1a). 
In contrast, no difference in reactivity to the SARS-CoV-2 nucleocapsid protein was 
identified (p = 0.99).    190 
 
To test responses to the S2 subunit of the SARs-CoV-2 spike protein we developed an S2 
indirect ELISA. In contrast to the other SARS-CoV-2 spike antigens measured by both the V-
PLEX assay and in-house ELISA, there was no difference in SARS-CoV-2 S2 ELISA 
responses the ICU fatal and non-fatal cohorts (Figure 2a: p = 0.99).  195 
 
Fatal COVID-19 outcomes were not associated with lower neutralising antibody titres as 
measured using a pseudotyped SARS-CoV-2 virus microneutralisation assay (Figure 2b, p = 
0.96). An R-PLEX ACE2 competition assay using the full-length spike and RBD as antigens 
was run to confirm this result. The R-PLEX assay showed no significant difference in binding 200 
inhibition between ACE2 and the spike protein (p = 0.83). However, there was significantly 
lower inhibition of binding between the RBD and ACE2 in the R-PLEX for individuals with 
fatal outcomes (Figure 2c; p = 0.02).  
 
 205 
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SARS-CoV-2 infection boosts responses to endemic beta-coronaviruses relative to disease 
severity 
 
We compared responses to HCoV spike antigens in the cohorts to determine how they 
correlated with COVID-19 severity. The fold-change in HCoV response was calculated by 210 
dividing the antibody titres of each sample by the average titre in the SARS-CoV-2 
seronegative blood donor cohort using the data show in Figure 1 (Figure 2a and Table S1, 
18).  
 
All cohorts previously infected with SARS-CoV-2 showed increased responses to the 215 
endemic beta-HCoV spike proteins relative to the unexposed background cohort (Figure 2a), 
suggesting that infection with SARS-CoV-2 induces increased cross-reactive responses, as 
reported elsewhere (10,12). No such trend was observed between the cohorts for antibody 
responses to alpha-HCoV spike proteins, which were comparable between all cohorts, 
irrespective of SARS-CoV-2 infection status.   220 
 
We found that the increased reactivity to the beta-HCoV spike proteins was also broadly 
associated with COVID-19 severity. The response to the HCoV-OC43 spike antigen was 
significantly larger for those admitted to ICU than either the infected (p = 2.93×10-6) or 
asymptomatic groups (p = 3.73×10-4; Figure 3a). Similar increases were observed for the 225 
beta-HCoV HKU1 spike protein, although these were smaller in magnitude in comparison to 
those associated with the HCoV-OC43 spike protein (Figure 3a). As with antibody responses 
to the HCoV-OC43 spike protein, those who had to be treated in ICU had statistically 
significantly higher HCoV-HKU1 spike responses compared to asymptomatic (p = 9.2×10-4) 
and infected (p = 2.85×10-7) groups. However, significantly higher responses to the HCoV-230 
HKU1 spike protein were not observed for those who were asymptomatic (p = 0.19) There 
was no significantly higher response to either the HCoV-OC43 (p = 0.07) or HCoV-HKU1 (p 
= 0.26) spike proteins in the SARS-CoV-2 antibody positive blood donor cohort.  
 
There was no comparative increase in antibody responses to alpha-HCoV (HCoV-NL63 and 235 
HCoV-229E) spike proteins following SARS-CoV-2 infection in either the blood donor or 
asymptomatic cohorts. However, smaller increases in responses to alpha-HCoV spike protein 
were detected in the fatal/non-fatal ICU cohorts and the antenatal control group. For all 
endemic coronaviruses, the antenatal cohort had an elevated HCoV response in comparison to 
blood donors, which could be not explained by biases in age or sex, but we suggest these 240 
trends could be due to environmental differences (Figure 1; Figure 3a).  
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Fatal COVID-19 outcomes are associated with a dominant immune response targeting 
shared beta-coronavirus epitopes 
 245 
We	  then	  analysed	  how	  the	  SARS-­‐CoV-­‐2	  antibody	  response	  correlated	  with	  the	  antibody	  
response	   to	   beta-­‐HCoV	   spike	   proteins.	  We	   calculated	   the	   Spearman’s	   rank	   correlation	  
coefficients	  for	  all	  pairs	  of	  antigens	  from	  the	  V-­‐PLEX	  assay,	  split	  by	  cohort	  (Figure	  3b).	  
Notably,	   in	   the	   fatal	   ICU	   cohort,	   responses	   to	   the	   SARS-­‐CoV-­‐2	   spike	   were	   strongly	  
correlated	  with	  the	  HCoV-­‐OC43	  and	  HCoV-­‐HKU1	  spike	  antigens	  (ρ	  =	  0.89,	  p	  =	  8×10-­‐8	  and	  250 
ρ	  =	  0.78,	  p	  =	  4×10-­‐5,	  respectively).	  Intriguingly,	  this	  correlation	  was	  present	  not	  only	  for	  
the	  full-­‐length	  spike	  antigen	  but	  also	  to	  the	  NTD	  (HCoV-­‐OC43	  p	  =	  5×10-­‐7;	  HCoV-­‐HKU1	  p	  
=	  4×10-­‐4)	  and	  RBD	  (HCoV-­‐OC43	  p	  =	  2×10-­‐5;	  HCoV-­‐HKU1	  p	  =	  3×10-­‐4)	  of	  the	  spike,	  as	  well	  
as	   the	   SARS-­‐CoV-­‐2	  nucleocapsid	   (HCoV-­‐OC43	  p	  =	  5.×10-­‐7;	  HCoV-­‐HKU1	  p	  =	  4×10-­‐4;	   see	  
Figure	   3b).	   We	   could	   not	   identify	   statistically	   significant	   correlations	   in	   the	   similarly	  255 
sized	   asymptomatic	   and	   non-­‐fatal	   ICU	   cohorts.	   Similar	   correlations	   with	   beta-­‐
coronaviruses	  were	  also	  found	  for	  the	  SARS-­‐CoV-­‐2	  spike	  S2	  subunit	  (Figure	  S3).	  
	  
A	  linear	  model	  fit	  on	  the	  log-­‐scale	  was	  used	  to	  analyse	  the	  correlation	  of	  the	  magnitude	  
of	  response	  to	  either	  the	  SARS-­‐CoV-­‐2	  NTD	  or	  RBD	  of	  the	  spike,	  the	  full-­‐length	  spike,	  and	  260 
the	   SARS-­‐CoV-­‐2	  nucleocapsid	   (Figures	   3c	  &	  d,	   Figure	   S2	   respectively)	  with	   the	  HCoV-­‐
HKU1	  and	  HCoV-­‐OC43	  spike	  responses	  in	  the	  asymptomatic	  and	  ICU	  cohorts.	  Responses	  
between	  SARS-­‐CoV-­‐2	  antigens	  and	   the	  beta-­‐HCoVs	   correlated	   strongly	   in	   the	   fatal	   ICU	  
cohort	  with	  consistently	  high	  R2	  values,	  indicating	  that	  for	  fatal	  COVID-­‐19	  outcomes	  the	  
SARS-­‐CoV-­‐2	  de	  novo	  antibody	  response	  is	  strongly	  linked	  with	  the	  responses	  to	  shared	  265 
SARS-­‐CoV-­‐2/HCoV	  spike	  protein	  epitopes.	  
	  
Preferentially	   targeted	   epitopes	   map	   to	   the	   S2	   subunit	   of	   the	   HCoV-­‐OC43	   spike	  
protein	  
	  270 
In	  fatal	  cases	  of	  COVID-­‐19,	  responses	  to	  shared	  epitopes	  in	  the	  HCoV-­‐OC43	  spike	  protein	  
increased	  in	  magnitude	  to	  a	  greater	  extent	  than	  those	  in	  the	  HCoV-­‐HKU1	  spike	  protein	  
(Figure	  3).	  To	   identify	   the	   location	  of	   the	  beta-­‐HCoV	  response	  causing	   the	  correlation,	  
we	  subdivided	  the	  HCoV-­‐OC43	  spike	  protein	  into	  the	  NTD	  (aa	  1-­‐419)	  as	  well	  as	  the	  S1	  
(aa	  1-­‐794)	  and	  S2	  (aa	  766-­‐1304)	  subunits	  of	  the	  spike	  protein	  (Figure	  4a).	  	  	  275 
	  
In	   response	   to	  both	   fatal	  and	  non-­‐fatal	  SARS-­‐CoV-­‐2	   infection,	   there	  was	  an	   increase	   in	  
response	  to	  all	  the	  HCoV-­‐OC43	  spike	  domains	  analysed,	  although	  the	  response	  to	  the	  S2	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subunit	  was	  considerably	  greater,	  indicating	  that	  the	  majority	  of	  shared	  SARS-­‐CoV-­‐2	  and	  
beta-­‐HCoV	  epitopes	  reside	  in	  the	  S2	  subunit.	  	  280 
	  
There	  were	  no	   significant	  differences	   in	   the	   fold-­‐change	  of	   responses	   to	   these	   specific	  
regions	  between	  ICU	  patients	  with	  non-­‐fatal	  and	  fatal	  COVID-­‐19	  outcomes	  (Figure	  3b).	  
There	  were	  median	  fold-­‐increases	  of	  6.93	  (p	  =	  1×10-­‐3),	  2.48	  (p	  =	  4×10-­‐3),	  31.4	  (p	  =	  2.×10-­‐
18)	  	  increases	  to	  the	  NTD,	  S1	  and	  S2	  HCoV-­‐OC43	  spike	  domains,	  respectively,	  across	  the	  285 
fatal	  and	  non-­‐fatal	  ICU	  cohorts	  in	  comparison	  to	  the	  blood	  donor	  control	  group.	  	  
	  
We	   fitted	   a	   linear	   regression	   between	   the	   log-­‐concentration	   of	   response	   between	   the	  
HCoV-­‐OC43	  responses	   (NTD,	  S1,	  S2	  and	  nucelocapsid)	  and	  either	   the	  SARS-­‐CoV-­‐2	   full-­‐
length	  spike	  protein	  or	  nucleocapsid	  (Figure	  4b).	  In	  those	  individuals	  with	  fatal	  COVID-­‐290 
19	  outcomes,	  there	  was	  a	  strong	  correlation	  between	  antibody	  responses	  to	  the	  HCoV-­‐
OC43	  S2	  subunit	  and	  the	  SARS-­‐CoV-­‐2	  spike,	  which	  extended	  to	  the	  SARS-­‐CoV-­‐2	  RBD	  and	  
NTD	  of	  the	  spike	  protein,	  as	  well	  as	  the	  SARS-­‐CoV-­‐2	  nucleocapsid	  (Figure	  4c).	  The	  SARS-­‐
CoV-­‐2	   spike	   S2	   subunit	   has	   previously	   been	   shown	   to	   be	   the	   target	   of	   antibodies	  
induced	  by	  prior	  endemic	  coronavirus	  infection	  (9,10;	  Figure	  4c).	   In	  contrast	  to	  the	  S2	  295 
spike	   subunit,	   antibody	   responses	   to	   both	   the	   HCoV-­‐OC43	   S1	   subunit	   and	   NTD	  
correlated	   poorly	   with	   SARS-­‐CoV-­‐2	   antibody	   response	   in	   fatal	   COVID-­‐19	   outcomes	  
(Figure	  4c).	  	  
	  
We	   then	   compared	   the	   response	   to	   the	   HCoV-­‐OC43	   nucleocapsid	   in	   individuals	   with	  300 
fatal	   and	   non-­‐fatal	   COVID-­‐19	   outcomes.	  Whilst	   the	   response	   to	   the	   SARS-­‐CoV-­‐2	   spike	  
was	   lower	   in	   those	  with	   fatal	   disease,	   the	   SARS-­‐CoV-­‐2	  nucleocapsid	   response	  was	  not	  
(Figure	  1).	  	  
	  
In	   comparison	   to	   the	   SARS-­‐CoV-­‐2	   spike	   response	  where	   responses	   to	   the	  HCoV-­‐OC43	  305 
increased	  upon	  SARS-­‐CoV-­‐2	   infection,	  no	   increase	   in	   antibody	   responses	   to	   the	  HCoV-­‐
OC43	  nucleocapsid	  were	  detected	  upon	  SARS-­‐CoV-­‐2	  infection	  (Figure	  4a).	  	  The	  non-­‐fatal	  
cohort	  had	  a	  median	  fold	  change	  of	  0.79	  (p	  =	  4×10-4),	  whilst	  there	  was	  no	  change	  for	  the	  
fatal	   cohort	   when	   compared	   to	   the	   control	   group	   (p	   =	   0.28).	   The	   absence	   of	   any	  
increased	   cross-­‐reactivity	   to	   the	  HCoV-­‐OC43	  nucleocapsid	   in	   individuals	   infected	  with	  310 
SARS-­‐CoV-­‐2	   indicates	   that	  unlike	   in	   the	  case	  of	   the	  SARS-­‐CoV-­‐2	  spike,	   the	  SARS-­‐CoV-­‐2	  
immune	  response	  was	  not	  targeting	  epitopes	  shared	  between	  the	  HCoV-­‐OC43	  and	  SARS-­‐
CoV-­‐2	   nucleocapsids	   (Figure	   4).	   Consequently,	   the	   nucleocapsid	   de	   novo	   response	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appears	  not	  to	  be	  linked	  with	  the	  responses	  to	  shared	  SARS-­‐CoV-­‐2/beta-­‐HCoV	  epitopes,	  






Our	  study	  shows	  that	  a	  dominant	   immune	  response	  targeting	  shared	  beta-­‐coronavirus	  
epitopes	  in	  the	  S2	  subunit	  of	  the	  spike	  protein	  is	  associated	  with	  fatal	  COVID-­‐19	  disease.	  
To	   date,	   this	   is	   the	   first	   study	   to	   associate	   previous	   exposure	   to	   HCoVs	   directly	   with	  
COVID-­‐19	  clinical	  outcomes.	  	  
	  325 
Our	   results	   are	   in	   line	  with	   previous	  work	   (22)	   showing	   higher	   neutralising	   antibody	  
titres	  and	  increased	  antibody	  levels	  to	  a	  range	  of	  beta-­‐coronavirus	  antigens	  in	  patients	  
with	  severe	  COVID-­‐19.	  However,	  in	  contrast	  to	  those	  studies,	  we	  found	  that	  titres	  were	  
significantly	   lower	   among	   patients	   with	   a	   fatal	   COVID-­‐19	   outcome.	   There	   was	   also	   a	  
strong	   correlation	   in	   the	   cohort	   with	   a	   fatal	   COVID-­‐19	   outcome	   between	   antibody	  330 
responses	  to	  SARS-­‐CoV-­‐2	  spike	  and	  nucleocapsid,	  and	  antibody	  responses	  to	  both	  HCoV-­‐
HKU1	   and	   HCoV-­‐OC43	   spike	   proteins.	   This	   correlation	   was	   shown	   to	   be	   due	   to	  
preferential	  targeting	  of	  the	  HCoV-­‐OC43	  S2	  subunit,	  but	  not	  the	  HCoV-­‐OC43	  NTD	  or	  S1	  
subunit	  (Figure	  3;	  9,10).	  
	  335 
These	  observations	  suggest	  that	  individuals	  with	  fatal	  COVID-­‐19	  outcomes	  are	  failing	  to	  
mount	   the	   same	   level	   of	   de	  novo	   immune	   responses	   to	   novel	   epitopes	   specific	   to	   the	  
SARS-­‐CoV-­‐2	  spike	  as	   those	  who	  had	  non-­‐fatal	  outcomes.	  This	  could	  reflect	  an	   immune	  
response	  that	  is	  influenced	  by	  past	  exposure	  to	  endemic	  beta-­‐coronaviruses,	  likely	  due	  
to	  the	  recall	  of	  memory	  B	  cells	  dominating	  the	  SARS-­‐CoV-­‐2	  response	  (23)	  abrogating	  or	  340 
diverting	  an	  effective	  new	  immune	  response	  to	  a	  new	  SARS-­‐CoV-­‐2	  infection.	  	  
	  
This	   hypothesis	   is	   supported	   by	   (i)	   previous	   publications	   demonstrating	   that	   the	  
majority	  of	  detectable	  cross-­‐reactive	  antibody	  response	  induced	  by	  prior	  HCoV	  infection	  
are	  directed	  at	  the	  S2	  subunit	  of	  the	  SARS-­‐CoV-­‐2	  spike	  (9,10),	  (ii)	  the	  strong	  correlation	  345 
between	   the	   antibody	   response	   to	   the	   S2	   subunit	   of	   the	  HCoV-­‐OC43	   spike	   induced	  by	  
SARS-­‐CoV-­‐2	   infection	  and	   the	   response	   to	   the	  SARS-­‐CoV-­‐2	   full-­‐length	  spike,	  NTD,	  RBD	  
and	  the	  nucleocapsid	  in	  fatal	  COVID-­‐19,	  and	  (iii)	  the	  inhibition	  of	  responses	  to	  the	  RBD,	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NTD	   and	   full-­‐length	   spike,	   but	   not	   the	   S2	   subunit	   or	   SARS-­‐CoV-­‐2	   nucleocapsid	   during	  
SARS-­‐CoV-­‐2	  infection.	  	  350 
	  
This	  mechanism	  may	  be	  reminiscent	  of	  original	  antigenic	  sin	  (OAS)	  as	  it	   involves	  prior	  
immune	   responses	   compromising	   the	   generation	   of	   de	   novo	   responses	   to	   a	   closely	  
related	  pathogen	  (24).	  Similar	  phenomena	  have	  been	  observed	  for	  dengue	  and	  influenza	  
viruses	  (25,26).	  However,	  it	  should	  be	  considered	  that	  the	  examples	  documented	  to	  date	  355 
relate	  to	  different	  variants	  or	  serotypes	  of	  the	  same	  pathogen.	  	  
	  
The	   inhibition	   in	   the	   development	   of	   de	  novo	   responses	   to	   new	   SARS-­‐CoV-­‐2	   epitopes	  
does	  not	  appear	  to	  extend	  to	  the	  SARS-­‐CoV-­‐2	  nucleocapsid	  protein.	  It	  seems	  that	  this	  is	  
due	   to	   the	  absence	  of	   targeted	   shared	  epitopes	  between	   the	  SARS-­‐CoV-­‐2	  and	  endemic	  360 
coronavirus	  nucleocapsids	   allowing	   sufficient	   recall	   of	  memory	  B	   cells	   to	   compromise	  
the	  development	  of	   responses	   to	  novel	  nucleoprotein	  protein	  epitopes	   (Figure	  3).	  The	  
absence	  of	  shared	  SARS-­‐CoV-­‐2/HCoV-­‐OC43	  nucleocapsid	  epitopes	  was	  demonstrated	  by	  
the	   absence	   of	   any	   increase	   in	   response	   to	   the	   HCoV-­‐OC43	   nucleocapsid	   upon	   SARS-­‐
CoV-­‐2	  infection.	  	  365 
	  
The	   timeframe	   of	   sampling	   has	   been	   suggested	   to	   be	   critical	   in	   the	   ability	   to	   identify	  
differences	   in	   the	   responses	   amongst	   severely	   ill	   COVID-­‐19	   patients	   (27).	   The	   single	  
timepoint	  sampled	  in	  this	  study	  limits	  the	  window	  in	  which	  the	  appearance	  of	  de	  novo	  
responses	  can	  be	  examined	  in	  fatal	  COVID-­‐19	  cases.	  Consequently,	  an	  earlier	  timepoint	  370 
might	  indicate	  that	  neutralising	  antibodies	  are	  generally	  lower,	  as	  opposed	  to	  only	  one	  
out	  of	  three	  neutralisation	  or	  ACE2	  binding	  assays	  showing	  this	  feature	  (Figure	  2).	  This	  
would	  match	  with	  the	  consistently	   lower	  IgG	  RBD,	  NTD	  and	  spike	  responses.	  Our	  data	  
proposes	   a	   probable	   mechanism	   for	   this	   feature	   –	   a	   dominant	   immune	   response	  
directed	  against	  shared	  beta-­‐HCoV	  epitopes	  in	  the	  S2	  subunit	  of	  the	  SARS-­‐CoV-­‐2	  spike.	  	  375 
	  
This	  study	   is	   further	   limited	  by	   the	  absence	  of	   longitudinal	  samples,	  which	  might	  help	  
determine	  why	  some	  individuals	  mount	  a	  targeted	  S2	  response	  whilst	  others	  do	  not.	  Our	  
HCoV-­‐OC43	   nucleocapsid	   protein	   assay	   shows	   this	   is	   not	   due	   to	   recent	   HCoV-­‐OC43	  
infection,	   which	   would	   have	   shown	   increased	   responses	   to	   HCoV-­‐OC43	   nucleocapsid	  380 
relative	  to	  the	  negative	  blood	  donor	  controls	  (Figure	  3c).	  The	  correlation	  between	  fatal	  
COVID-­‐19	  and	  the	  observed	  targeted	  antibody	  response	   is	   likely	  due	  to	  an	   individual’s	  
past	   history	   of	   infection	   with	   HCoV-­‐OC43/-­‐HKU1.	   However,	   whether	   the	   key	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contributing	  factors	  are	  age,	  sex,	  time,	  since	  the	  last	  beta-­‐coronavirus	  infection,	  infection	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Ethical	   approval	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   for	   the	   Scottish	   National	   Blood	   Transfusion	   Service	  
(SNBTS)	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   archive	   -­‐	   IRAS	  project	   number	   18005.	   SNBTS	  blood	  donors	   gave	  
fully	  informed	  consent	  to	  virological	  testing,	  donation	  was	  made	  under	  the	  SNBTS	  Blood	  495 
Establishment	  Authorisation	  and	   the	   study	  was	   approved	  by	   the	   SNBTS	  Research	  and	  
Sample	  Governance	  Committee.	  
	  
The	   ISARIC	  WHO	  CCP-­‐UK	  protocol	  was	  developed	  by	   international	  consensus	   in	  2012-­‐
14	  and	  activated	  in	  response	  to	  the	  SARS-­‐CoV-­‐2	  pandemic	  on	  17th	  January	  2020.	  This	  is	  500 
an	   actively	   recruiting	   prospective	  cohort	   study	   recruiting	   across	   the	   United	   Kingdom	  
(28).	   Study	   materials	   including	  protocol,	   revision	   history,	   case	   report	   forms,	  study	  
information	   and	   consent	  forms,	   are	   available	   online	   [https://isaric4c.net/protocols/].	  
Ethical	  approval	  was	  given	  by	  the	  South	  Central	  -­‐	  Oxford	  C	  Research	  Ethics	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   England	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  13/SC/0149)	   and	  by	   the	   Scotland	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  Research	   Ethics	   Committee	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The	  antenatal	  samples	  were	  collected	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  antenatal	  care	  appointments	  in	  the	  
Oxfordshire	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  Samples	  were	  taken	  during	  the	  first	  trimester	  of	  pregnancy	  (generally	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  8–12 weeks’	   gestation)	  between	  14	  April	   and	  15	   June	  2020.	  Ethical	   approval	  510 
was	  obtained	  from	  the	  South-­‐Central	  Research	  Ethics	  Committee	  (Ref:	  08/H0606/139).	  
	  
Patients	   and	   healthcare	  workers	   comprising	   the	   asymptomatic	   cohort	   were	   recruited	  
from	  the	   John	  Radcliffe	  Hospital	   in	  Oxford, 	  United	  Kingdom,	  between	  March	  and	  May	  
2020.	  Patients	  identified	  during	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  SARS-­‐COV-­‐2	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  were	  screened	  and	  recruited	  515 
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  Immunomics	  (IRAS260007)	  and	  International	  Severe	  Acute	  Respiratory	  
and	  Emerging	  Infection	  Consortium	  World	  Health	  Organization	  Clinical	  Characterisation	  
Protocol	  UK	  (IRAS126600).	  Patients	  were	  sampled	  at	   least	  28	  days	   from	  their	  positive	  
RT-­‐PCR	   test.	   The	   ICU	   patients	   were	   enrolled	   as	   part	   of	   an	   ongoing	   prospective	  
observational	   study	   AspiFlu	   (ISRCTN51287266)	   at	   St	   George’s	   Hospital,	   London,	   UK.	  520 
Researchers	   working	   with	   the	   samples	   in	   the	   laboratory	   were	   blinded	   to	   the	   clinical 
outcomes	   of	   the	   ICU	   patients	   during	   testing.	    None of the study subjects received 
convalescent plasma therapy.	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Enzyme-­‐linked	  immunosorbent	  assay	  525 
	  
SARS-­‐CoV-­‐2	  spike,	  RBD	  as	  well	  as	  HCoV-­‐229E,	  HCoV-­‐NL63,	  HCoV-­‐HKU1	  and	  HCoV-­‐OC43	  
spike	   IgG	   antibody	   responses	   were	   measured	   using	   ELISAs.	   Further	   work	   to	  
characterise	  the	  location	  of	  the	  conserved	  epitopes	  between	  HCoV-­‐OC43	  and	  SARS-­‐CoV-­‐
2	  used	  the	  HCoV-­‐OC43,	  NTD,	  S1	  and	  S2	  subunits.	  Spike	  and	  RBD	  proteins	  were	  produced	  530 
as	  per	  Armanat	  et	  al	  2020	  (29).	  HCoV-­‐229E,	  HCoV-­‐NL63,	  HCoV-­‐HKU1	  and	  HCoV-­‐OC43	  
spike	   antigens	  were	   bought	   from	   Sino	  Biological,	   China.	   The	   S1	   and	   S2	   proteins	  were	  
bought	  from	  Sino	  Biological,	  China	  an	  the	  OC43	  NTD	  from	  The	  Native	  Antigen,	  UK.	  
	  
Nunc-­‐Immuno	   96-­‐well	   plates	   (Thermo	   Fischer	   Scientific,	   USA)	   were	   coated	   with	  535 
1.0 μg ml−1	  of	  antigen	   in	  PBS	  buffer	  and	   left	  overnight	  at	  4 °C.	  Plates	  were	  washed	  with	  
3x	  with	  0.1%	  PBS–Tween	  (PBS/T),	  then	  blocked	  with	  casein	  in	  PBS	  for	  1 hour	  at	  room	  
temperature	   (RT).	   Serum	   or	   plasma	   was	   diluted	   in	   casein–PBS	   solution	   at	   dilutions	  
ranging	   from	  1:50	   to	   1:20,000	   before	   being	   added	   to	  Nunc-­‐Immuno	   96-­‐well	   plates	   in	  
triplicate.	  Plates	  were	   incubated	  for	  2	  hours	  before	  being	  washed	  with	  6x	  with	  PBS/T.	  540 
Secondary	   antibody	   rabbit	   anti-­‐human	  whole	   IgG	   conjugated	   to	   alkaline	   phosphatase	  
(Sigma,	  USA)	  was	  added	  at	  a	  dilution	  of	  1:1000	  in	  casein–PBS	  solution	  and	  incubated	  for	  
1 hour	   at	   RT.	   After	   a	   final	   wash,	   plates	   were	   developed	   by	   adding	   4-­‐nitrophenyl	  
phosphate	   substrate	   in	  diethanolamine	  buffer	   (Pierce,	  Loughborough,	  UK),	   and	  optical	  
density	   (OD)	   was	   read	   at	   405 nm	   using	   an	   ELx800	   microplate	   reader	   (Cole	   Parmer,	  545 
London,	  UK).	  A	  reference	  standard	  comprising	  of	  pooled	  cross-­‐reactive	  serum	  and	  naïve	  
serum	  on	  each	  plate	  served	  as	  positive	  and	  negative	  controls,	  respectively.	  
	  
The	  positive	  reference	  standard	  was	  used	  on	  each	  plate	  to	  produce	  a	  standard	  curve.	  A	  
monoclonal	  antibody	  standard	  was	  used	  for	  the	  RBD/spike	  ELISAs.	  Pooled	  HCoV	  highly	  550 
reactive	  sera	  were	  used	  as	  a	  standard	  for	  the	  HCoV	  spike	  ELISAs.	  	  
	  
Protein	  sequences	  used	  in	  ELISAs	  
Protein	   Expressed	  in	  	   Provider	   Reference	  (if	  
appropriate)	  
HCoV-­‐HKU1	  spike	  	   Insect	  cells	   Sino	  Biological	   	  
HCoV-­‐OC43	  spike	  	   Insect	  cells	   Sino	  Biological	   	  
HCoV-­‐NL63	  spike	  	   Insect	  cells	   Sino	  Biological	   	  
HCoV-­‐229E	  spike	  	   Insect	  cells	   Sino	  Biological	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SARS-­‐CoV-­‐2	  spike	  	   HEK	  293T	   Produced	  in-­‐house	   Amanat	  et	  al	  2020	  
(29)	  




HEK	  293T	   Sino	  Biological	   	  
HCoV-­‐OC43	   S1	  
subunit	  
HEK	  293T	   Sino	  Biological	   	  
HCoV-­‐OC43	   S2	  
subunit	  	  
Insect	  cells	   Sino	  Biological	   	  




	   	  555 
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MSD	  V-­‐PLEX	  assay	  
	  
IgG	  antibody	  responses	  to	  SARS-­‐CoV-­‐2	  spike,	  RBD,	  NTD	  and	  nucleocapsid	  and	  the	  spike	  
proteins	   of	   SARS-­‐CoV-­‐1,	   HCoV-­‐229E,	   HCoV-­‐NL63,	   HCoV-­‐HKU1	   and	   HCoV-­‐OC43	   were	  
assessed	  using	  the	  Meso	  Scale	  Diagnostics	  (MSD)	  Multi-­‐Spot	  Assay	  System	  (MSD,	  USA).	  560 
Pre-­‐coated	   plates	   (‘Coronavirus	   panel	   2’)	   were	   incubated	   at	   room	   temperature	   (RT)	  
with	   Blocker	   A	   solution	   for	   at	   least	   30	  minutes	  whilst	   being	   shaken	   at	   500-­‐700	   rpm.	  
Serum	   or	   plasma	   was	   diluted	   in	   Diluent	   100	   at	   dilutions	   of	   1:500	   to	   1:50,000	   and	  
samples	  were	  added	  to	  the	  plates	  in	  duplicate.	  Plates	  were	  incubated	  for	  2	  hours	  at	  RT,	  
whilst	   being	   shaken	   at	   500-­‐700	   rpm	   throughout.	   A	   1x	   working	   concentration	   of	   the	  565 
SULFO-­‐TAG	   anti-­‐human	   IgG	   Detection	   Antibody	   was	   prepared	   in	   Diluent	   100.	   After	  
incubation	   with	   the	   samples,	   the	   plates	   were	   washed	   x3	   with	   1x	   MSD	   Wash	   buffer.	  
Prepared	  detection	  antibody	  solution	  was	  added	  to	  the	  plates,	  which	  were	  incubated	  at	  
RT	   for	   1	   hour,	   whilst	   being	   shaken.	   Plates	   were	   then	   washed	   x3	   with	   1X	  MSD	  Wash	  
buffer.	  To	  read	  the	  assay	  results,	  MSD	  GOLD	  Read	  Buffer	  B	  (provided	  ready	  to	  use)	  was	  570 
added	   to	   the	   plate.	   No	   incubation	   is	   required,	   and	   the	   plates	   were	   read	   on	   a	   MESO	  
QuickPlex	  SQ	  120	  (MSD,	  USA)	  immediately	  after	  adding	  the	  buffer.	  
	  
A	   7-­‐point	   calibration	   curve	   of	   the	   standards	  was	   prepared	   using	  Diluent	   100.	   Diluent	  
100	  was	  used	  as	  a	  negative	  control.	  An	  additional	  three	  positive	  controls	  provided	  with	  575 
the	  kit	  were	  also	  run	  on	  every	  plate.	  All	  standards	  and	  controls	  were	  run	   in	  duplicate.	  
Data	   from	   the	   assay	   was	   analysed	   using	   MSD	   Discovery	  Workbench	   software,	   which	  
averaged	  all	  the	  duplicates,	  generated	  and	  fitted	  all	  the	  data	  to	  standard	  curves.	  	  
	  
MSD	  ACE2	  competition	  assay	  580 
	  
The	  ability	  of	  antibodies	  present	  in	  serum/plasma	  to	  inhibit	  the	  binding	  of	  angiotensin-­‐
converting	   enzyme	   2	   (ACE2)	   to	   the	   SARS-­‐CoV	   full-­‐length	   spike	   proteins	   and	   RBD	  
domains	   was	   assessed	   using	   the	   COVID-­‐19	   ACE2	   competition	   assay	   (MSD,	   USA).	   The	  
assay	  can	  be	  used	  to	  estimate	   the	  neutralising	  activity	  of	   the	  antibodies	  present	   in	   the	  585 
samples.	  
	  
Pre-­‐coated	  plates	  were	  incubated	  at	  RT	  with	  Blocker	  A	  solution	  for	  at	  least	  30	  minutes	  
whilst	   being	   shaken	   at	   500-­‐700	   rpm.	   Serum	   or	   plasma	  was	   diluted	   in	   Diluent	   100	   at	  
dilutions	  of	  1:10	  to	  1:100	  and	  samples	  were	  added	  to	  the	  plates	  in	  duplicate.	  Plates	  were	  590 
incubated	   for	   1	   hour	   at	   RT,	   whilst	   being	   shaken	   at	   500-­‐700	   rpm	   throughout.	   A	   1x	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working	   concentration	   of	   the	   SULFO-­‐TAG	   ACE2	   detect	   was	   prepared	   in	   Diluent	   100.	  
After	   incubation	   with	   the	   samples,	   the	   plates	   were	   washed	   x3	   with	   f	   1x	   MSD	   Wash	  
buffer.	   Prepared	   SULFO-­‐TAG	   ACE2	   solution	   was	   added	   to	   the	   plates,	   which	   were	  
incubated	  at	  RT	  for	  a	   further	  1	  hour,	  whilst	  being	  shaken.	  Plates	  were	  then	  washed	  x3	  595 
with	  1X	  MSD	  Wash	  buffer.	  To	  read	  the	  assay	  results,	  MSD	  GOLD	  Read	  Buffer	  B	  (provided	  
ready	   to	   use)	  was	   added	   to	   the	   plate.	   Plates	  were	   read	   immediately	   after	   adding	   the	  
buffer	  on	  a	  MESO	  QuickPlex	  SQ	  120	  (MSD,	  USA)	  
	  
A	   7-­‐point	   calibration	   curve	   of	   the	   standards	  was	   prepared	   using	  Diluent	   100.	   Diluent	  600 
100	  was	  used	  as	  a	  negative	  control.	  All	  standards	  were	  run	  in	  duplicate.	  Data	  from	  the	  
assay	  was	  analysed	  using	  MSD	  Discovery	  Workbench	  software,	  which	  averaged	  all	   the	  
duplicates,	  generated	  and	  fitted	  all	  the	  data	  to	  standard	  curves.	  	  
	  
Pseudotyped	  virus	  microneutralisation	  assay	  605 
	  
A	  lentivirus-­‐based	  pseudotyped	  virus	  system	  was	  used	  to	  display	  the	  SARS-­‐CoV-­‐2	  spike	  
protein	   on	   its	   surface	   using	   a	   synthetic	   codon	   optimised	   SARS-­‐CoV-­‐2	   expression	  
construct	  (NCBI	  reference	  sequence:	  YP_009724390.1).	  	  
	  610 
Target	   cells	   were	   transfected	   24	   hours	   prior	   to	   assay	   setup	   with	   2.75	   ug	   of	   ACE2	  




Over	   dispersed	   variables	   were	   transformed	   onto	   the	   logarithmic	   scale	   (base	   10)	   for	  
between	  group	  comparisons	  for	  V-­‐PLEX	  platform	  concentrations,	  ELISA	  optical	  density	  
and	  neutralising	  titres.	  Unless	  otherwise	  specified,	  a	  t-­‐test	  assuming	  unequal	  variances	  
was	   used	   to	   test	   for	   differences	   in	   the	  mean	   responses;	   values	  were	   analysed	   on	   the	  
logarithmic	  (base	  10)	  scale	  unless	  otherwise	  stated.	  A	  Holm	  correction	  was	  applied	  to	  p-­‐620 
values	  for	  multiple	  comparisons.	  In	  cases	  where	  a	  fold	  change	  or	  ratio	  is	  calculated,	  the	  
log-­‐scale	  group	  means	  can	  be	  compared	  to	  zero	  using	  a	  t-­‐test	  to	  determine	  if	  the	  group	  
differs	  from	  equal	  concentrations	  of	  antigens.	  For	  non-­‐normal	  variables	  that	  do	  not	  meet	  
the	   assumptions	  of	   normality	   –	   even	   if	   transformed	  –	   a	  Dunn’s	   test	  was	  used	   instead.	  
Reported	   correlations	   are	   Spearman’s	   rank,	   as	   the	   measure	   is	   non-­‐parametric	   and	  625 
robust	  to	  transformation.	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  Figures 675 
 
Table 1. Features of sample cohorts analysed 
Cohort   N   Identification   Sampling  stage   Clinical   features  
Sex  
(Female,   
n,   %)  
Age  
(Median,   
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Figure 1: Individuals with fatal COVID-19 make lower responses to the SARS-
CoV-2 spike protein, but not the SARS-CoV-2 nucleocapsid. a. Boxplots comparing 695 
antibody concentrations for each antigen. Sample groups (background uninfected, 
infected, asymptomatic and ICU) are given on the x-axis. Sub-groups are denoted by 
colour. The average response to all SARS-CoV-2 antigens were elevated in ICU 
patients, and no differences were observed between the infected and asymptomatic 
groups. Fatal ICU patients made a lower response to SARS-CoV-2 RBD (p = 0.01), 700 
spike (p = 0.02) and NTD (p = 0.02) than non-fatal ICU patients. The data in this 



































Figure 2: S2 ELISA responses and neutralising antibody responses cannot 
distinguish between severe non-fatal and fatal COVID-19. a. Antibody responses 
directed against the S2 subunit of the SARS-CoV-2 spike protein. There was no 725 
statistical difference between antibody responses directed at the S2 subunit of the 
SARS-CoV-2 spike in individuals with fatal and non-fatal COVID-19. Data generated 
by indirect ELISA. b. Neutralising antibody levels correlate with disease severity 
but cannot distinguish between severe non-fatal and fatal COVID-19. Samples 
were tested using a SARS-CoV-2 pseudotype microneutralisation assay. 730 
Neutralisation titres were higher in the ICU cohorts than the blood donor, antenatal 
and asymptomatic groups, but there was no significant difference based on clinical 
outcomes of ICU stay (p = 0.99).  c. ACE2 inhibition assay results. Samples were 
also analysed with an R-PLEX ACE2 inhibition assay (MSD). The level of ACE2 
binding inhibition was not statistically significant for the spike, but the fatal ICU 735 
cohort shows statistically lower ACE2-RBD binding inhibition in comparison to the 
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Figure 3: In fatal COVID-19, antibody responses to SARS-CoV-2 are highly 
correlated with antibody responses to the endemic beta-coronavirus spike proteins. 760 
a. Mean fold-change of antibodies to endemic coronaviruses. Antibodies to 
endemic beta-coronaviruses are boosted by SARS-CoV-2 infection and broadly 
correlate with COVID-19 severity. The mean fold-change to each spike protein was 
determined by dividing the average response to each antigen by responses in the 
background blood donor group (Table 1). Broad classifications of COVID-19 clinical 765 
presentations are given on the x-axis, with colour denoting sub-groups. A larger fold-
change in OC43 and HCoV-HKU1 responses was observed in the ICU cohort relative 
to the blood donor, antenatal and asymptomatic groups, but not between infected and 
asymptomatic cohorts. The same increases were not observed for alpha-
coronaviruses. There were no significant differences observed in the mean fold 770 
changes between the fatal and non-fatal ICU cohorts for any endemic HCoV. The data 
in this figure were generated using the ELISA-based MSD V-PLEX assay b. 
Correlations between SARS-COV-2 and endemic coronavirus responses. 
Spearman’s rank correlations (ρ) are shown for each pair of antigens, split by sample 
group. There is a positive correlation between all SARS-CoV-2 antigens in all but the 775 
background blood donor group. Significant correlations are found between SARS-
CoV-2 epitopes and endemic beta-HCoVs (OC43 and HCoV-HKU1) in the positive 
blood donor, antenatal and fatal ICU groups; these correlations are absent in the 
asymptomatic and non-fatal ICU groups. The correlation between endemic beta-
HCoVs and SARS-CoV-2 epitopes are considerably weaker in the larger positive 780 
blood donor and antenatal cohorts than in the fatal ICU samples. c. and d. Responses 
to the SARS-CoV-2 spike (c) and receptor-binding domain (d) correlate with 
beta-coronavirus spike responses in fatal COVID-19. Select correlations are shown 
in c. with a linear model fit between the concentration of two SARS-CoV-2 antigens 
and the endemic viruses OC43 and HCoV-HKU1. Data are shown only for sample 785 
groups with a clinical definition of COVID-19 severity (asymptomatic, non-fatal and 
fatal, across panel rows). The best fit line is shown in blue with 95% confidence 
intervals in grey; the dotted grey line denotes a 1:1 response to both antigens. There is 
a strong positive association between SARS-CoV-2 Spike/RBD and the endemic 
coronaviruses in the fatal ICU patients that is absent in the asymptomatic and non-790 
fatal ICU patients.  
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Figure 4: Antibody responses are directed against the S2 subunit of the HCoV-795 
OC43 spike protein. a. Fold-change in responses to various domains/subunits in 
the HCoV-OC43 spike protein and nucleocapsid. Indirect ELISAs were run against 
the N-terminal domain (NTD), S1 subunit and S2 subunit of the HCoV-OC43 spike 
protein, in addition to the HCoV-OC43 nucleocapsid. Fold-change via ELISA was 
determined relative to the average value in the SARS-CoV-2 negative blood donor 800 
cohort. Antibody levels are increased against all antigens apart from the nucleocapsid, 
with the largest increase in antibody response to the S2 subunit of the spike protein. b. 
Correlation in responses between SARS-CoV-2 antigens and HCoV-OC43 spike 
protein domains and nucleocapsid.  The log-scale OD405 values from the HCoV-
OC43 spike and nucleocapsid ELISA (along the rows) is compared to the MSD V-805 
PLEX SARS-CoV-2 results (columns). A linear model is fit on the log-scale is 
annotated with the associated 95% confidence intervals, R2 and p-value. Values and 
model fits for the non-fatal ICU samples is given in purple, while red is used for the 
fatal group. The HCoV-OC43 S2 subunit ELISA result is correlated with the 
concentration of SARS-CoV-2 antibodies, but only in the fatal group. c. Correlations 810 
between ELISAs and MSD V-PLEX SARS-CoV-2 assay responses. Responses to 
the S2 subunit of HCoV-OC43 are strongly correlated with the MSD concentration of 
SARS-CoV-2 antibodies in those who died from coronavirus, but not those who 
survived. Notably, there is a positive correlation between the S2 subunit response and 
the HCoV-OC43 Spike and HCoV-HKU1 concentrations in both cohorts, suggesting 815 
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Supplementary	  Material	  
	  
Figure	  S1:	  Correlation	  of	  MSD	  VPLEX	  and	  ELISA	  data.	  The	  correlation	  of	  results	  across	  
the	   two	   assays	   for	   the	   SARS-­‐CoV-­‐2	   full-­‐length	   spike	   and	   RBD	   domains,	   along	   with	  825 
endemic	  coronavirus	  spike	  antigens	  is	  shown,	  with	  Spearman	  Rank	  correlations	  .	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Figure	  S2:	  Ratio	  of	  SARS-­‐CoV-­‐2	  RBD	  response	  to	  spike	  response	  as	  measured	  by	  MSD	  








Figure	  S3:	  Correlations	  of	  the	  S2	  ELISA	  antibody	  responses	  in	  fatal	  and	  non-­‐fatal	  individuals	  with	  
SARS-­‐CoV-­‐2	  and	  HCoV	  antigens.	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S6:	  Days	  from	  post-­‐symptomatic	  and	  entry	  to	  ICU	  in	  the	  fatal	  and	  non-­‐fatal	  groups.	  In	  both	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